Odonate Therapeutics, Inc. announced that in connection with the discontinuation of development of tesetaxel, Joseph O’Connell, M.D. mutually agreed with Odonate to terminate his employment effective July 31, 2021. Dr. O’Connell had served as Odonate’s Chief Medical Officer.